A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours
2015 ◽
Vol 51
(16)
◽
pp. 2275-2284
◽
Keyword(s):
Phase I
◽
2008 ◽
Vol 44
(13)
◽
pp. 1829-1834
◽
Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours
2002 ◽
Vol 38
(15)
◽
pp. 1992-1997
◽
1995 ◽
Vol 6
(2)
◽
pp. 193-196
◽